Alpha 1 Biomedicals, Cel-Sci infectious diseases/aids news

CELI said it will file for arbitration against ALBM concerning their Viral Technologies Inc. joint venture, which is developing HGP-30, a potential HIV vaccine.

CELI said that ALBM, citing its financial position, has said it will discontinue paying its 50 percent share of the venture's expenses. ...